Abstract Library

#4252 Intra-arterial Peptide Receptor Radionuclide Therapy in a Filipino male with predominantly hepatic metastasis in a known primary pancreatic neuroendocrine tumor

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) has shown positive clinical outcomes in somatostatin receptor (SSTR) overexpressing positive well-differentiated neuroendocrine tumors in combination with somatostatin analogue therapy. A noted decreased progression-free survivability in the use of PRRT has been noted in larger lesions (>3cm).

Conference:

Presenting Author: Azarraga C

Authors: Azarraga C, Leogardo D, Bandong I, Bautista-Peñalosa P,

Keywords: neuroendocrine, PRRT, intra-arterial, bulky,

#3981 Identifying patients with undiagnosed small intestinal neuroendocrine tumors using statistical and machine learning: Model development and validation study

Introduction: Diagnosis of small intestinal neuroendocrine tumors (SI-NETs) is often delayed due to non-specific symptoms and lack of awareness among primary and secondary care physicians. Earlier diagnosis may lead to improved clinical and patient outcomes. Clinical prediction models using machine learning could present novel opportunities for expedited diagnosis in primary care.

Conference:

Presenting Author:

Authors: Clift A, Mahon H, Khan G, Boardman-Pretty F, Worker A,

Keywords: machine learning, artificial intelligence, diagnosis, neuroendocrine tumor,

#3920 Complete and sustained response after peptide receptor radionuclide therapy in a 66-year-old Filipino male with metastatic pancreatic neuroendocrine tumor: A case report primary

Introduction: The introduction of peptide receptor radionuclide therapy (PRRT) to the Philippines has allowed for novel approaches in the management of neuroendocrine tumors (NETs).

Conference:

Presenting Author: Chianpian C

Authors: Chianpian C, Bautista-Peñalosa P, Santos C, Bandong I,

Keywords: peptide receptor radionuclide therapy, metastatic pancreatic neuroendocrine tumor, Ga-68 DOTATATE, Lu-177 DOTATATE, Philippines,

#3882 Adjuvant therapy for pancreatic neuroendocrine tumors – Expert consensus and recommendations for future research

Introduction: With the increase of incidentally diagnosed pancreatic neuroendocrine tumors (panNEN), more patients are treated with curative intent. Survival in patients with a panNEN is impacted by the development of recurrence, but postoperative adjuvant therapy is not yet recommended in guidelines due to absence of evidence. Multiple clinicopathological characteristics have been described in literature to identify patients at high-risk of recurrence who might benefit from adjuvant treatment. Since panNEN are rare tumors, prospective randomized controlled studies on the role of adjuvant therapy in these patients have not been performed.

Conference:

Presenting Author: Heidsma C

Authors: Heidsma C, Engelsman A, Klümpen H, Falconi M, Frilling A,

Keywords: pancreatic neuroendocrine tumor, recurrence, adjuvant therapy, prevention, expert consensus, future research,

#2213 Imaging Modality Depending on the Levels of Tumor Markers

Introduction: 18 F-Fluorodihydroxyphenylalanine(18F)-FDOPA positron emission tomography (PET)/computed tomography (CT) has the advantage of being a noninvasive test and is by far the most promising imaging modality for neuroendocrine tumors (NETs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Iorio J

Authors: Iorio J, Eleta M, Cuneo L, Polillo D, Peña F,

Keywords: neuroendocrine tumors, tumor marker, 18F-FDOPA, PET/CT,